Comparative Pharmacology
Head-to-head clinical analysis: VISINE versus VISINE L R.
Peer-Reviewed Evidence
Head-to-head clinical analysis: VISINE versus VISINE L R.
VISINE vs VISINE L.R.
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Tetrahydrozoline is a sympathomimetic amine that acts as an alpha-1 adrenergic receptor agonist, causing vasoconstriction of conjunctival blood vessels, thereby reducing redness and edema.
Selective alpha-1 adrenergic receptor agonist; constricts conjunctival blood vessels via stimulation of alpha-1 adrenoreceptors in the ophthalmic artery, reducing redness and edema.
1-2 drops in affected eye(s) every 6-8 hours as needed, not to exceed 4 times daily.
1 to 2 drops in the affected eye(s) every 8 to 12 hours, not to exceed 2 drops per eye every 8 hours. Ophthalmic solution 0.05%.
None Documented
None Documented
Approximately 1-2 hours for ocular absorption; systemic half-life not clinically relevant due to low systemic absorption
Terminal elimination half-life is 2.1 ± 0.2 hours for the racemic mixture; clinical context: dosing intervals typically every 4-6 hours.
Primarily renal as unchanged drug and metabolites; minor biliary/fecal elimination (<10%)
Primarily renal excretion of unchanged drug and metabolites; ~90% of an oral dose is excreted in urine within 24 hours; biliary/fecal excretion accounts for <5%.
Category C
Category C
Ophthalmic Decongestant
Ophthalmic Decongestant